Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Scooter Gennet
Too true. I was at the game on Sunday. Puig cost the Dodgers 2 outs on baserunning blunders...little league mistakes....the kind of BS that kills a team in October.
Dapper Don better work it out with this punk. Grady Little was shiitcanned by the Red Sox for less.....
Yup. There are some very big details left out of the email and the recent PRs. Specific $$ amounts, # of shares involved in transactions, etc aren't proving very helpful if you look at the PPS slide. And with the timing of the PRs, clearly meant to bolster the PPS before shares hit the market, one would be foolish not be a tad suspicious here.
That said, this is currenly trading at .007 while generating revenue and income. Better than many weed stocks now in vogue.
Anthony Anish
from the website: became a Director in early 2011 and is currently the Company Secretary and Chief Operating Officer. Mr Anish has considerable management experience in many industries including electronics, aerospace, accounting and has consulted with many Companies providing financial expertise and lines of credit for many of his customers. Mr. Anish has been the General Manager of M Line Holdings, Inc. since March 2009 and has overseen the recovery of the group during the very difficult economic downturn. Now, as COO, Mr. Anish is positioning the Company for significant growth. Mr. Anish qualified as a member of the Institute of Chartered Accountants in London, England in 1971.
From the company. Sent on a Saturday night I might add:
Hi XXXXXXXX, we are also very upset about the way that the share price has dropped over the last few weeks. We did do a couple of 3A9 transactions that buy back debt for stock and we believe that as much as they promise to feed shares into the market slowly this is probably at least a part of the cause of the drop.
As we have reported we continue to make progress in the Company with good results and continuing growth. WE feel that this drop in market value will stop and although we are desperately disappointed we have added a large number of new shareholders and generated volume in the stock which was not there previously.
Please "keep the faith" with the shares as we truly believe it will start heading in the other direction shortly.
We truly believe in what we are doing. We are very concerned about shareholder value and will take whatever steps that are possible to change that position. Obviously I cannot give information to you that is not available to the public but action is being taken which we hope will correct this.
As far as the increase in share capital has been concerned there was a complete breakdown in communication between our attorneys and the Company. The fact that I have been out the last week with a kidney stone issue also slowed this down. It will be dealt with next week.
XXXXXXX, please do not hesitate to contact me at any time and I will do my utmost to respond to you with as much information as I am able to give.
Can I add you to our shareholder list for Email notifications in the future.
LOLLLLLLLLLLL. This is better than Monty Frickin' Python and the Holy Grail... the scene where the king of the swamp tries to give his guards instructions to watch the princess....
You've done enough here TF.
TY. I sent off an email through the company website asking for clarification and explanation of the A/S.
Just back from opening night in Sydney. Clayton looked sharp, Yasiel looked lost, but the real story for me was the Dodgers pen. Chris Perez in the 7th, the beard in the 8th and Kenley slamming the door in the 9th.
Tomorrow I'll see if the formula can be repeated with Ryu.
NEPT added at 2.49. Chen Lin has made me a lot of $$ in the past 5 years.
http://seekingalpha.com/article/2038643-chen-lins-perfect-biotech-market-prescription-buy-low-sell-high
Also added ETRM at 2.15. $heff has made me even more!
NL MVP: Lucas Duda!!!!!!
AXXU just getting started. Up 20% on excellent volume.
Winner of AL East Rays
2nd In AL East Yanks
Winner of AL Central Tigers
2nd In AL Central Royals
Winner of AL West A's
2nd In AL West Rangers
AL Wildcard #1 Royals
AL Wildcard #2 Yanks
Winner of NL East nats
2nd In NL East Braves
Winner of NL Central Reds
2nd In NL Central Brewers
Winner of NL West Dodgers
2nd In NL West Giants
NL Wildcard #1 Brewers
NL Wildcard #2 Cards
Team With Best Record In Baseball Tigers
Team With Worst Record In Baseball Astros
TB # 1: Who hits the most HR in Baseball (Combined) Braun
TB # 2: Who has the Most RBIS in Baseball (Combined) Prince
I disagree. tanaka sells tickets. who's gonna buy the E santana bobblehead doll? and tanaka is an unknown. garza and jimenez and santana are proven mediocre commodities.....innings eaters at best.
choo had his career year last year....and he's already hurt.....and the yanks had to pull ellsbury from within the division. beltran? yup, gotta agree he's a bit long in the tooth....and the 4th place finish might indeed happen or they may sneak in behind the rays for the wc if tex, jeter and cc turn it around.
big pick for this year: the crew take a wc in the nl. braun makes it all the way back and estrada finishes in the top 5 for the cy@!
the 100k was mine- doubled down on an earlier buy. I'm ready to sit on this one for a while- with increasing revs, new management and a fantastic industry, I can wait til the rest of the investment crowd catches on.
That has to be one of the funniest, most ludicrous statements I've read in some time:
"because a lot of traders wouldn't invest in pot companies for moral reasons....."
AXXU bought a few at .28
Company has increasing revs and has scraped up an MJ angle that hasn't been pumped dry by the Maryjane-1200%-in-1/2-day crew. Yet.
SS is decent and a bit of exposure to this news should do the trick:
http://www.axxessunlimited.com/index.php
Another little Scooby snack here:
http://finance.yahoo.com/news/axxess-unlimited-reports-date-2013-133000981.html
Maybe a treat at under .008
Could be. That's the basement floor. But the wheels are now in motion; and do think for a minute that Liberty and ICL put money into AAA without microscopic DD and a view to a future priced well over .47 a share? (and .80 in the case of Liberty).
Bingo! Very strategic to do a deal with a partner like ICL who has a lot of skin in the game
Each Unit issued pursuant to the Offering consists of a common share of the Company (a "Common Share"), one and one half Series A Common Share purchase warrants (the "Series A Warrants") and one half of one Series B Common Share purchase warrant (the "Series B Warrants", and collectively with the Series A Warrants, the "Warrants"). Each whole Warrant will be exercisable for one Common Share for a period of 36 months from issuance of the Warrant. Each whole Series A Warrant will be exercisable for a price of $0.54 per Common Share, and each whole Series B Warrant will be exercisable for a price of $0.60 per Common Share.
ICL has agreed to purchase the entire production of the Project up to 1Mtpa with a take-or-pay commitment of ICL on a minimum of 80% of output from the Project.
And I don't think Liberty is going to sit on their thumbs after paying .80 per share in the past:
In addition, the Company may issue Units to Liberty Metals and Mining Holdings, LLC and/or IFC, in such amount as is required to be issued upon due exercise of their respective pre-emptive rights with respect to the Second Tranche.
I'm in. TIA
I suspect you're right. And I also suspect these are brutal negotiations.
But looking back at Farhad's dealings, how good does the last PP at .80 look today?
ATOS
My order to buy filled at 2.48. Reading the PR, I like that the recall was voluntary. Also, the problem seems to be with the wording of the instructions rather than a fundamental problem with the hardware.
Hopefully the FDA meeting led to clarity about how to write the instructions for use and the limitations of the device so that full approval can happen:
Atossa is removing the ForeCYTE Breast Health Test and the MASCT device from the market to address concerns raised by the U.S. Food and Drug Administration (FDA) in a warning letter received by Atossa in February 2013. The FDA raised concerns about (1) the current instructions for use (IFU); (2) certain promotional claims used to market these devices; and (3) the need for FDA clearance for certain changes made to the Nipple Aspirate Fluid (NAF) specimen collection process identified in the current IFU. Atossa will remove existing product from the market until FDA's concerns are addressed.
I bought in here as a catalyst play under .50 and am considering getting greedy. In the next few days the ?'s I need to DD are:
1. Will the FDA will approve VersaFilm?
2. Are there any glaring omissions in the NDA application which send up a red flag?
3. What would approval mean for the PPS?
I suspect there are more than a few like me who bought for the % move. Anyone see a major trader bail out before the PDUFA date driving down the PPS?
TIA and GLTA
Good call. Nice bump into the HOD on building volume. looking for a move over $2.75 on this run.
I'm in at $2.28 here. It may dip lower, but the upcoming Fabry data and the lessening of dilution fear should make for a sweet run into the end of June.
FOLD 2.29
bought some FOLD. $82 million cash on hand, top line data for Fabry due in June.
http://finance.yahoo.com/news/amicus-therapeutics-provides-full-2014-123000037.html
Get financially real: comparing the tobacco industry to the MMJ industry is like comparing Harvard to a one room log school house. The prisons of America aren't packed with tobacco offenders at 220k per year of taxpayer money. The MMJ industry doesn't contribute huge amounts to federal and local governments across the country. The populations of Columbia and Mexico haven't seen over 100,000 deaths due to cartels fighting to control tobacco sales.
It's never been a question of danger with MMJ or tobacco: it's a moral question underpinned by a puritanical-christian ethos which hearkens back to the absurdities of prohibition. Danger is a relative concept and few would question that both MMJ and tobacco (along with booze and all other drugs) are dangerous. But the danger and the true damage done by outlawing these drugs rather than regulating and financially benefiting from them has been historically documentable; legalization does not equate to endorsement. You don't have to smoke pot to see the benefits of legalization (though it helps!!!).
And as for addiction, big tobacco has been allowed to pump their products with additives to foster addiction and has spent 100's of millions in defense of their products even while they knew that they were in the wrong. With MMJ, many lontime pot smokers would concur that after years of smoking weed, it does indeed require a massive personal effort to break the addiciton....to ice cream and Doritos!
Wow. Amazing returns since 2009 Sheff. Here's to your continued success, health and happiness!
I wish you a speedy and full recovery SSKILLZ. All the best.
CANF $8.60
Roth ups target to $28. Phase 3 results for dry eye due before the end of the year
http://www.streetinsider.com/Analyst+Comments/Can-Fite+BioPharma+%28CANF%29+Target+Raised+to+$28+at+Roth+Capital/9003631.html
Fantastic work GHMM! Looking forward to seeing your picks next time around. Thanks SSKILLZ1 for another excellent contest!
CANF $6.46
From Oct 1, 2013 PR
Roth Capital Partners has initiated coverage of Can-Fite BioPharma (OTCQB:CANFY; TASE:CFBI) with a “buy” rating and $15 price target, suggesting investors own the stock ahead of two data readouts in the fourth quarter this year.
Can-Fite is an Israeli company, whose ADRs recently started trading in the U.S. They closed at $5.03 on Monday.
BuyThe company’s most advanced products are CF101, CF102, and CF602. The underlying technology is based on targeting the adenosine A3 receptor (A3AR), which has been shown to be overexpressed in inflammatory and tumor cells.
According to analyst Joseph Pantginis, the current quarter should be very telling for the Can-Fite story.
“The primary stock driver should be the readout of a Phase 2b using CF101 in rheumatoid arthritis patients,” he said. “The company is taking some important lessons learned from previous studies and we believe is giving the study the best shot possible by prospectively identifying patients who have high expression levels of the CF101’s target (the A3A Receptor).”
Mr. Pantginis believes the data from this study will be positive and “act as a potential launching point to drive confidence in the drug and the overall platform in the U.S.”
Also in fourth quarter, a Phase 3 study will read out in a 231 patient study using CF101 in dry eye syndrome, which is being run by OphthaliX.
“As we await the Phase 2b results for CF101 in rheumatoid arthritis, it is important to point out that screening for A3AR expression levels prospectively in patients can be the first ever biological marker used to drive treatment decisions for RA,” Mr. Pantginis said.
Disclosures:
ROTH and/or its employees, officers, directors and owners own options, rights or warrants to purchase shares of Can-Fite
Bio Pharma stock.
Within the last twelve months, ROTH has received compensation for investment banking services from Can-Fite Bio Pharma.
ROTH makes a market in shares of Can-Fite Bio Pharma and as such, buys and sells from customers on a principal basis.
Shares of Can-Fite Bio Pharma may be subject to the Securities and Exchange Commission's Penny Stock Rules, which
may set forth sales practice requirements for certain low-priced securities.
Shares of Can-Fite Bio Pharma may not be eligible for sale in one or more states.
CANF
ADR trading at $6.46
Started a position in CANF. News due before the end of the year on 2 studies.
http://finance.yahoo.com/news/fite-ceo-issues-letter-shareholders-120000151.html
More info from a WSJ article here: http://online.wsj.com/article/PR-CO-20131120-904735.html
Priced below October offering of $6.60
Lots of action here, though not the traditional FDA pathway.
Better luck winning the gold in Brazil....
Thanks for your insights. See you in a year. Don't let the door hit you in the mineshaft....
Why would you post this again?
Sure do. Every time I think about TGTX.
Ever tried to do biz in Nigeria? How many companies that pump out 10k+ barrels a day do you know of that trade for MMT's 1 buck PPS?
Wade is hamstrung. And the bad guys are the ones with government offices.
I'm pretty impressed Wade has gotten Mart this far along, because of course the bigger Mart gets, the more $$ corrupt Nigerian officials want off the top. I just hope bribe money is a company write off and not liable to government excise.
JBII is the same -- attempting to decorate the globe with P2O machines since day 1.
And all this time I thought the company's goal was to make oil from plastic....guess a P2O machine could look handsome next to the birdbath in the back yard.....